Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (14)

2023

  1. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

    International Journal of Cardiology, Vol. 370, pp. 51-57

2022

  1. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 8, pp. 777-785

  2. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

2021

  1. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials

    Journal of the American College of Cardiology, Vol. 77, Núm. 19, pp. 2366-2377

  2. The 2020 ESC-ACVC quality indicators for the management of acute myocardial infarction applied to the FAST-MI registries

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 2, pp. 207-215

2020

  1. Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 5, pp. 375-398

2019

  1. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

    European Respiratory Journal, Vol. 54, Núm. 3

  2. Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 8, pp. 745-754

2017

  1. Assessment of Quality Indicators for Acute Myocardial Infarction in the FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) Registries

    Circulation: Cardiovascular Quality and Outcomes, Vol. 10, Núm. 6

  2. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial

    The Lancet, Vol. 389, Núm. 10081, pp. 1799-1808

  3. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction

    Journal of the American College of Cardiology, Vol. 69, Núm. 22, pp. 2710-2720

2016

  1. Contemporary management of acute right ventricular failure: A statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 18, Núm. 3, pp. 226-241